Gilead Sciences, Inc. (NASDAQ:GILD) Stake Raised by D.A. Davidson & CO.

D.A. Davidson & CO. boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 92,415 shares of the biopharmaceutical company’s stock after acquiring an additional 2,685 shares during the period. D.A. Davidson & CO.’s holdings in Gilead Sciences were worth $6,541,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. raised its position in Gilead Sciences by 1.9% in the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after buying an additional 1,937,031 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Gilead Sciences by 1.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after purchasing an additional 310,607 shares during the period. Franklin Resources Inc. grew its stake in Gilead Sciences by 1.0% in the 2nd quarter. Franklin Resources Inc. now owns 14,516,058 shares of the biopharmaceutical company’s stock valued at $1,027,436,000 after purchasing an additional 136,884 shares during the period. Legal & General Group Plc grew its stake in Gilead Sciences by 9.3% in the 2nd quarter. Legal & General Group Plc now owns 7,004,455 shares of the biopharmaceutical company’s stock valued at $495,778,000 after purchasing an additional 596,992 shares during the period. Finally, TIAA CREF Investment Management LLC grew its stake in Gilead Sciences by 8.8% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 6,267,271 shares of the biopharmaceutical company’s stock valued at $443,597,000 after purchasing an additional 509,260 shares during the period. 76.23% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $73.29 on Wednesday. The firm has a market capitalization of $95,475.20, a price-to-earnings ratio of 7.63, a PEG ratio of -1.22 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. Gilead Sciences’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.75 earnings per share. research analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.84%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.69%.

A number of research analysts have issued reports on the company. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Zacks Investment Research downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Vetr downgraded Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 target price for the company. in a research note on Monday, September 4th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $83.00 target price (up previously from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and a consensus target price of $85.22.

In other news, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the transaction, the chief financial officer now owns 43,352 shares of the company’s stock, valued at $3,684,920. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $82.65, for a total value of $2,066,250.00. The disclosure for this sale can be found here. Insiders have sold 546,819 shares of company stock valued at $41,808,839 in the last three months. 1.30% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/12/06/gilead-sciences-inc-gild-holdings-lifted-by-d-a-davidson-co.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply